2008•Unpublished venueRequires access

Etravirine: A non-nucleoside reverse transcriptase inhibitor for the treatment of resistant HIV-1 infection

Bryan L. Love, Jacqueline L. Olin, Heather A. Kehr

Abstract

Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that was approved January 18, 2008, for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in antiretroviral treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to NNRTIs and other antiretroviral agents.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Etravirine, Nucleoside Reverse Transcriptase Inhibitor, Medicine, Reverse-transcriptase inhibitor, Reverse transcriptase, Virology, Human immunodeficiency virus (HIV), Nucleoside